Elacestrant

(Orserdu®)

Orserdu®

Drug updated on 1/3/2024

Dosage FormTablet (oral; 86mg, 345 mg)
Drug ClassEstrogen receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of postmenopausal women or adult men, with ER positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.